BIND Biosciences secures $12.4m financing
BIND Biosciences, a Cambridge biopharmaceutical company that looks to use a proprietary medicinal nanoengineering platform to develop new drugs, said it has secured a $12.4 million Series C-1 financing.
"This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors," BIND said in a press release.
BIND's lead product candidate is BIND-014, a nanoparticle cancer therapeutic targeted to a clinically-validated solid tumor antigen.,
"The support from new and existing investors to take our lead product, BIND-014, into the clinic this year and move our second product towards the clinic next year is a significant step forward for BIND," BIND president and chief executive Scott Minick said in a statement.
In a separate press release, BIND announced today the appointment of Ed Schnipper, M.D., as the company's chief medical officer. Previously, Schnipper was vice president of clinical development at ALZA Corp.
Comment
Permalink
E-mail
- By Email Business Updates newsletter
